Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Accumulated Expenses (2017 - 2025)

Crinetics Pharmaceuticals has reported Accumulated Expenses over the past 9 years, most recently at $35.6 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $35.6 million for Q4 2025, up 23.16% from a year ago — trailing twelve months through Dec 2025 was $35.6 million (up 23.16% YoY), and the annual figure for FY2025 was $35.6 million, up 23.16%.
  • Accumulated Expenses for Q4 2025 was $35.6 million at Crinetics Pharmaceuticals, up from $32.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CRNX hit a ceiling of $35.6 million in Q4 2025 and a floor of $3.2 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $11.0 million (2022), compared with a mean of $14.3 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 137.03% in 2024 and later rose 6.97% in 2025.
  • Crinetics Pharmaceuticals' Accumulated Expenses stood at $6.6 million in 2021, then surged by 37.84% to $9.1 million in 2022, then surged by 59.86% to $14.5 million in 2023, then surged by 98.99% to $28.9 million in 2024, then grew by 23.16% to $35.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $35.6 million (Q4 2025), $32.4 million (Q3 2025), and $21.8 million (Q2 2025) per Business Quant data.